Stockscreener 앱 받기
15.89
1.34%
0.21
시간 외 거래:
16.10
0.21
+1.32%
전일 마감가:
$15.68
열려 있는:
$16.46
하루 거래량:
3.70M
Relative Volume:
1.13
시가총액:
$1.68B
수익:
$2.18B
순이익/손실:
$-64.32M
주가수익비율:
-16.48
EPS:
-0.9641
순현금흐름:
$91.18M
1주 성능:
-5.59%
1개월 성능:
-5.70%
6개월 성능:
-28.33%
1년 성능:
+33.19%
1일 변동 폭
$15.88
$16.69
1주일 범위
$15.43
$17.22
52주 변동 폭
$11.68
$25.32
사렙타 테라퓨틱스 Stock (SRPT) Company Profile
명칭
Sarepta Therapeutics Inc
전화
617-274-4000
주소
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT vs VRTX, REGN, ARGX, RVMD, ALNY
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
15.89 | 1.66B | 2.18B | -64.32M | 91.18M | -0.9641 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
사렙타 테라퓨틱스 Stock (SRPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Equal Weight |
| 2025-12-09 | 개시 | Wedbush | Outperform |
| 2025-11-05 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-09-22 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-29 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2025-07-29 | 개시 | Bernstein | Mkt Perform |
| 2025-07-29 | 재확인 | H.C. Wainwright | Sell |
| 2025-07-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2025-07-29 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-07-28 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2025-07-25 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-07-24 | 개시 | Citigroup | Sell |
| 2025-07-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2025-07-22 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-07-21 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-07-21 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2025-07-21 | 다운그레이드 | Needham | Hold → Underperform |
| 2025-07-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-07-18 | 다운그레이드 | Needham | Buy → Hold |
| 2025-06-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-06-17 | 개시 | Wolfe Research | Peer Perform |
| 2025-06-16 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-06-16 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | 다운그레이드 | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-04-11 | 개시 | Wells Fargo | Overweight |
| 2025-04-02 | 업그레이드 | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-11-27 | 재확인 | Needham | Buy |
| 2024-11-25 | 개시 | H.C. Wainwright | Sell |
| 2024-11-07 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | 개시 | Jefferies | Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-07-29 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-05-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-01-31 | 개시 | BMO Capital Markets | Outperform |
| 2023-12-13 | 재개 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-11-21 | 개시 | Wedbush | Outperform |
| 2023-10-31 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-04-26 | 개시 | SMBC Nikko | Outperform |
| 2023-04-04 | 개시 | Citigroup | Buy |
| 2023-03-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | 재확인 | BTIG Research | Buy |
| 2022-12-16 | 업그레이드 | UBS | Neutral → Buy |
| 2022-04-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-01-05 | 재확인 | Needham | Buy |
| 2021-12-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-05 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-09-15 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-08-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-01-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-01-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-01-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | 개시 | Berenberg | Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-20 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | 개시 | Mizuho | Buy |
| 2019-11-01 | 개시 | Guggenheim | Buy |
| 2019-08-21 | 재확인 | Needham | Buy |
| 2019-07-09 | 재확인 | Morgan Stanley | Overweight |
| 2019-07-01 | 재확인 | RBC Capital Mkts | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-11 | 재확인 | Credit Suisse | Outperform |
| 2018-10-12 | 개시 | Bernstein | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-26 | 재확인 | RBC Capital Mkts | Outperform |
| 2018-09-14 | 재개 | BofA/Merrill | Buy |
| 2018-09-06 | 개시 | Credit Suisse | Outperform |
| 2018-08-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | 재확인 | Robert W. Baird | Outperform |
| 2018-06-20 | 재확인 | Needham | Buy |
| 2018-06-19 | 재확인 | H.C. Wainwright | Buy |
모두보기
사렙타 테라퓨틱스 주식(SRPT)의 최신 뉴스
Sarepta names Michael Severino, former Tessera CEO, as new chief executive - STAT
SRPT Looks 87.5% Undervalued on GF Value™ - GuruFocus
Former AbbVie, Amgen exec Severino takes the reins at Sarepta - FirstWord Pharma
Morgan Stanley Views Sarepta CEO Transition As A ‘Positive’ – So, Why Is It Cautious On SRPT Stock In The Near Term? - Stocktwits
Capricor Therapeutics (NASDAQ:CAPR) shares tumble 67% after FDA raises concerns over Deramiocel data - TechStock²
Sarepta taps AbbVie, Tessera vet Severino to write Duchenne firm's next chapter - Fierce Pharma
FDA staff flags data concerns about Capricor's therapy; shares plunge - Reuters
Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO - BioPharma Dive
Sarepta taps AbbVie, Tessera vet Severino to write Duchenne firm's next chaper - Fierce Pharma
Sarepta Names Former AbbVie Executive Michael Severino New CEO - Bloomberg
Sarepta names former Abbvie president as CEO as Ingram retires - Reuters
Why is Sarepta Therapeutics stock climbing today? By Investing.com - Investing.com South Africa
Sarepta names former AbbVie R&D exec Michael Severino as next CEO - BioSpace
Cambridge biotech taps external executive to lead after Elevidys controversy - The Business Journals
Sarepta Therapeutics Appoints Michael Severino as CEO - TipRanks
Sarepta names Michael Severino as new CEO, Ingram retires - Investing.com
Sarepta Therapeutics Inc (SRPT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Sarepta Therapeutics (SRPT) Appoints New CEO, Shares Surge 7% - GuruFocus
Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer - Business Wire
How (SRPT) Movements Inform Risk Allocation Models - Stock Traders Daily
Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study - Stocktwits
Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat - Stocktwits
SRPT|Sarepta Therapeutics Inc|Price:15.680|Chg%:-0.200 - TradingKey
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - Stocktwits
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Stocktwits
SRPT Stock Drops 4% As Citi Flags Potentially Stronger Rival In Duchenne Space - Stocktwits
SRPT Stock Plunges 7% After-Hours As Elevidys Demand Slumps — CEO Still Sees Return To Growth - Stocktwits
SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are Signaling - Stocktwits
Sarepta Therapeutics Market Sentiment - Benzinga España
Skorney: FDA's Sarepta Precedent Makes Dyne DMD Approval 'Impossible' to Deny - finance.biggo.com
Sarepta Therapeutics, Inc. Revenue Breakdown – NASDAQ:SRPT - TradingView
Sarepta Therapeutics Inc (SRPT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Sarepta Therapeutics stock steadies as investors weigh Elevidys expansion and revenue trajectory - Ad-hoc-news.de
SRPT: Sarepta Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results - Finviz
SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat? - The Globe and Mail
Press Release: Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results - Moomoo
Sarepta Therapeutics Stock Short Interest Rises to 32.62% - Quiver Quantitative
Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Exploring a 28.77% Potential Upside for Investors - DirectorsTalk Interviews
Has Sarepta Therapeutics (SRPT) Fallen Below Fair Value After FDA Progress? - Sahm
uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix - TradingView
This Analyst Sees 34% Upside For SRPT Stock — Here's Why They Expect A Sustained Rally Next - Stocktwits
Trading Systems Reacting to (SRPT) Volatility - Stock Traders Daily
SRPT Stock Clocks Highest Daily Gain In Nearly 8 Years After Rare Muscle Disorders Study Data But Wall Street's Not Wholly Convinced - Stocktwits
Sarepta Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Sarepta Therapeutics, Inc. (SRPT) - Supply Chain Digital
Is Sarepta Therapeutics (SRPT) Undervalued Following FDA Progress On AMONDYS 45 And VYONDYS 53? - Sahm
Following FDA sNDA Acceptance Is Sarepta Therapeutics (SRPT) Still Undervalued? - Yahoo Finance
The Bull Case For Sarepta Therapeutics (SRPT) Could Change Following FDA sNDA Acceptance On DMD Therapies - Yahoo Finance
Sarepta Therapeutics (SRPT) Stock Analysis: Evaluating a 16.53% Potential Upside Amidst a Volatile Biotech Landscape - DirectorsTalk Interviews
사렙타 테라퓨틱스 (SRPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.97%
0.83%
자본화:
|
볼륨(24시간):